Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18901982 | 1.00 | KMT2A (0.41) | KMT2AMAPTNPC1RAB9AHPGD | |
| SCHEMBL12333081 | 0.97 | KMT2A (0.40) | KMT2AMAPTNPC1RAB9AHPGD | |
| SCHEMBL12686973 | 0.91 | NPC1 (0.41) | KMT2ANPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL1293820 | 0.90 | ALDH1A1 (0.36) | KMT2AMAPTNPC1RAB9AL3MBTL1 | |
| SCHEMBL883147 | 0.85 | KMT2A (0.41) | KMT2AMAPTNPC1RAB9AHPGD | |
| SCHEMBL1294457 | 0.84 | NPC1 (0.36) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL1294688 | 0.84 | NPC1 (0.36) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL12686982 | 0.84 | USP30 (0.50) | NPC1RAB9AALDH1A1 | |
| SCHEMBL18901586 | 0.84 | USP30 (0.50) | NPC1RAB9AALDH1A1 | |
| SCHEMBL1294687 | 0.84 | NPC1 (0.36) | NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-2773634-B1 | ROD-LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2-[4-(BIPHENYL-4-YL)-1H-IMIDAZO-2-YL]PYRROLIDINE-1-CARBONLYMETHYL}AMINE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9738629-B2 | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-22 | — | — | US | disclosed |
| US-9738629-B2 | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-22 | — | — | US | disclosed |
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-16 | — | — | US | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| WO-2012154777-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012109080-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012039717-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | KMT2A 3141/4885MAPT 3411/4885NPC1 32/4885 |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | KMT2A 4287/4885MAPT 4328/4885NPC1 191/4885 |
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KMT2A 4516/4885MAPT 4065/4885NPC1 65/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | KMT2A 3803/4885MAPT 2923/4885NPC1 516/4885 |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KMT2A 4516/4885MAPT 4065/4885NPC1 65/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KMT2A 3803/4885MAPT 2923/4885NPC1 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.